Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: A randomized, double-blind, placebo-controlled trial

Menopause

Volumn 17, Issue 5, 2010, Pages 908-916

  Joffe, Hadine ^a   Partridge, Ann ^b   Giobbie Hurder, Anita ^b   Li, Xiaochun ^b   Habin, Karleen ^a   Goss, Paul ^a   Winer, Eric ^b   Garber, Judy ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Antidepressant; Breast cancer; Hot flashes; Insomnia; Quality of life; Selective serotonin reuptake inhibitor; Serotonin norepinephrine reuptake inhibitor; Sleep; Vasomotor symptoms; Zolpidem

Indexed keywords

CITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; VENLAFAXINE; ZOLPIDEM;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP PATTERN; SLEEP WAKING CYCLE; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HOT FLASHES; HUMANS; HYPNOTICS AND SEDATIVES; MIDDLE AGED; PLACEBOS; PYRIDINES; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS, INTRINSIC;

EID: 77957700121     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181dbee1b     Document Type: Article

References (50)

1. Shaver J, Giblin E, Lentz M, Lee K. Sleep patterns and stability in perimenopausal women. Sleep 1988;11:556-561.
2. Woodward S, Freedman RR. The thermoregulatory effects of meno-pausal hot flashes on sleep. Sleep 1994;17:497-501.
3. Erlik Y, Tataryn IV, Meldrum DR, Lomax P, Bajorek JG, Judd HL. Association of waking episodes with menopausal hot flushes. JAMA 1981;245:1741-1744.
4. Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006;166:1262-1268.
5. Kravitz HM, Ganz PA, Bromberger J, Powell LH, Sutton-Tyrrell K, Meyer PM. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. Menopause 2003;10:19-28.
6. Young T, Rabago D, Zgierska A, Austin D, Laurel F. Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. Sleep 2003;26:667-672.
7. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-358.
8. Thurston RC, Blumenthal JA, Babyak MA, Sherwood A. Association between hot flashes, sleep complaints, and psychological functioning among healthy menopausal women. Int J Behav Med 2006;13:163-172.
9. Carpenter JS, Gautam S, Freedman RR, Andrykowski M. Circadian rhythm of objectively recorded hot flashes in postmenopausal breast cancer survivors. Menopause 2001;8:181-188.
10. Albright DL, Voda AM, Smolensky MH, Hsi B, Decker M. Circadian rhythms in hot flashes in natural and surgically-induced menopause. Chronobiol Int 1989;6:279-284.
11. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358.
12. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J Pain Symptom Manage 2000;19:436-445.
13. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995;13:2737-2744.
14. Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected problem. J Clin Oncol 2001;19:895-908.
15. Savard J, Simard S, Blanchet J, Ivers H, Morin CM. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001;24:583-590.
16. Mourits MJ, Bockermann I, de Vries EG, et al. Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapy. Br J Cancer 2002;86:1546-1550.
17. Thurston RC, Bromberger JT, Joffe H, et al. Beyond frequency: who is most bothered by vasomotor symptoms? Menopause 2008;15:841-847.
18. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659-2669.
19. Hickey M, Saunders C, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669-1680.
20. Thase ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci 2006;8:217-226.
21. Mai E, Buysse DJ. Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Sleep Med Clin 2008;3:167-174.
22. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-1886.
23. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
24. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
25. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
26. Douglass AB, Bornstein R, Nino-Murcia G, et al. The Sleep Disorders Questionnaire. I: creation and multivariate structure of SDQ. Sleep 1994; 17:160-167.
27. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999;282:1737-1744.
28. Buysse DJ, Reynolds CFD, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
29. Frisch MB, Cornell J, Villaneuva M. Clinical validation of the Quality of Life Inventory: a measure of satisfaction for in treatment planning and outcome assessment. Psychol Assess 1992;4:92-101.
30. Frisch MB. Manual and Treatment Guide for the Quality of Life Inventory. Minneapolis, MN: National Computer Systems, 1994.
31. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
32. Freedman RR. Laboratory and ambulatory monitoring of menopausal hot flashes. Psychophysiology 1989;26:573-579.
33. Carpenter JS, Andrykowski MA, Freedman RR, Munn R. Feasibility and psychometrics of an ambulatory hot flash monitoring device. Menopause 1999;6:209-215.
34. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-571
35. American Academy of Sleep Medicine, ed. The International Classification of Sleep Disorders: Diagnostic and Coding Manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine, 2005.
36. Dorsey CM, Lee KA, Scharf MB. Effect of zolpidem on sleep in women with perimenopausal and postmenopausal insomnia: a 4-week, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2004;26:1578-1586.
37. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early post-menopause: a randomized controlled trial. Obstet Gynecol 2006;108: 1402-1410.
38. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and post-menopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol 2010;202: 171.e1-171.e11
39. Lynn Henry N, Rae JM, Li L, et al. Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. Breast Cancer Res Treat 2009;117:571-575.
40. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-1436.
41. Besset A, Tafti M, Villemin E, Borderies P, Billiard M. Effects of zolpidem on the architecture and cyclic structure of sleep in poor sleepers. Drugs Exp Clin Res 1995;21:161-169.
42. Holms KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000;59:865-889.
43. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003;26:793-799.
44. Thase ME. Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group. J Clin Psychiatry 1997;58:393-398.
45. Gursky JT, Krahn LE. The effects of antidepressants on sleep: a review. Harv Rev Psychiatry 2000;8:298-306.
46. Luthringer R, Toussaint M, Schaltenbrand N, et al. A double-blind, placebo-controlled evaluation of the effects of orally administered venlafaxine on sleep in inpatients with major depression. Psychophar-macol Bull 1996;32:637-646.
47. Salin-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997;58:348-350.
48. DeVane CL. Differential pharmacology of newer antidepressants. J Clin Psychiatry 1998;59:85-93.
49. Loprinzi CL, Diekmann B, Novotny PJ, Stearns V, Sloan JA. Newer antidepressants and gabapentin for hot flashes: a discussion of trial duration. Menopause 2009;16:883-887.
50. Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007;25:308-312.